For ccRCC patients, we found that the biomarkers CIBERSORT.CD8, gene.CD8 and the T cell-inflamed GEP, IFN-gamma, CYT and PD-L1 provided the relatively better performance in the two cohorts (Figure 5B and Figure S23, mean AUC = 0.8, 0.78, 0.78, 0.76, 0.75, 0.73, respectively). The gene discussed is CD8A; the disease is nonpapillary renal cell carcinoma.